Several cases discuss the decision-making process regarding whether treatment should be considered for the advanced stage of age-related macular degeneration and whether that treatment should include ranibizumab, bevacizumab, or another therapy. In addition, decisions regarding need for additional treatment at follow-up and the approach to follow-up are discussed with these cases.